A
Aimmune Therapeutics
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company
About Aimmune Therapeutics
Aimmune Therapeutics is a biopharmaceutical company dedicated to developing innovative pharmaceutical therapies aimed at preventing, managing, and treating food allergies, gastrointestinal (GI) disorders, and metabolic diseases. The company is committed to transforming the lives of patients and their families by providing solutions for potentially life-threatening conditions. Aimmune operates primarily in the United States but has additional offices in Durham, North Carolina; Bridgewater, New Jersey; London, England; Dublin, Ireland; and Munich, Germany.
Aimmune's primary clients include patients and caregivers dealing with severe food allergies and related conditions, as well as healthcare professionals who prescribe and manage these treatments. The company operates in the healthcare and pharmaceutical market, focusing on niche areas with significant unmet medical needs.
The business model of Aimmune revolves around the research, development, and commercialization of pharmaceutical products. The company invests heavily in clinical trials and regulatory approvals to bring new treatments to market. Once approved, these treatments are sold to healthcare providers and directly to patients through various distribution channels. Aimmune generates revenue through the sale of these pharmaceutical products, as well as through partnerships and collaborations with other healthcare organizations.
Aimmune is committed to ethical business practices and compliance with all applicable laws, including the California Health and Safety Code. This commitment ensures that all operations are conducted transparently and ethically, fostering trust among patients, caregivers, and healthcare professionals.
In summary, Aimmune Therapeutics is a specialized biopharmaceutical company focused on developing treatments for food allergies, GI disorders, and metabolic diseases, serving patients, caregivers, and healthcare professionals, and generating revenue through the sale of its innovative pharmaceutical products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- San Mateo, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Longitude Capital
Foresite Capital
Adage Capital
Fidelity Investments
Aisling Capital
RA Capital Management
Series B and later1 investor entered at this stage
Nestlé Health Science
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aimmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aimmune Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.